NCT07243834Recruiting
Assessing a Digital Exercise Intervention for Health Outcomes and Engagement in Regular Exercise
Assessing a Digital Exercise Intervention for Health Outcomes and Engagement in Regular Exercise (ADHERE): A Randomised Controlled Trial Comparing the Efficacy of a Digital Exercise Intervention With Virtual Supervised Group Exercise Sessions to Standard of Care on Exercise Adherence at Six Months in Patients With Prostate Cancer Undergoing Hormone Therapy.
Source: ClinicalTrials.gov · Last updated 30 Jan 2026
Brief summary (registry, in English)
Patients diagnosed with prostate cancer and receiving hormone therapy in conjunction with radiotherapy are likely to suffer from adverse effects caused by ADT treatment either short term or long term. The most common side effects include changes in body composition leading to increased visceral fat and reduced lean muscle mass, increased risk of cardiovascular events and fatigue, which overall lower quality of life. There is strong evidence to support exercise interventions in minimising, and in some cases reversing many ADT -related toxicities, but exercise adherence remains a challenge for people living with prostate cancer, particularly due to logistical barriers to attendance such as cost and travel time, as well as insufficient motivation. The aim of this single centre, phase III randomised controlled trial is to assess the efficacy of a new digital exercise programme with virtual supervised group exercise sessions in improving adherence to exercise guidelines. The trial aims to recruit 160 participants with prostate cancer undergoing ADT, who will be allocated either the standard of care group or standard of care plus participation in the digital exercise intervention on a 1:1 ratio. Adherence to physical activity will be measured using a wearable accelerometer, an exercise diary, self-reported questionnaires and clinic based assessments at 3 months, 6 months and 12 months post radiotherapy treatment. Recruitment will take place at the Royal Marsden NHS Foundation Trust, Chelsea.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 160 (estimated)
- First submitted
- 17 Nov 2025
- Start date
- 16 Dec 2025
- Primary completion date
- 31 Jul 2028
- Lead sponsor
- Royal Marsden NHS Foundation Trust
- Diseases
- Prostate cancer
- NCT number
- NCT07243834
What you commit to
- Study type: Interventional
- Planned participants: 160
- From 16 Dec 2025 to the primary completion date, 31 Jul 2028
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Men planned to receive an androgen receptor-targeted agent (ARTA) or chemotherapy
Other illness
- Absolute contraindication to exercise as defined by ACPICR standards. This includes:
- New symptoms of angina
- New or unstable heart failure
- Newly diagnosed diabetes that is not controlled
- New or untreated arrhythmias
- Resting tachycardia or new bradycardia (not linked to changes in medications)
- Symptomatic hypotension
- Uncontrolled hypertension (SBP ≥ 180mmHg or DBP≥ 100mmHg)
Other
- Unstable spinal bone metastasis or at high risk of a fracture
- Musculoskeletal issue inhibiting exercise
Who the study is looking for
- Age \> 18 at randomisation
- Men with histological confirmation of prostate adenocarcinoma who are receiving or planned to receive ADT with an LHRHa as part of their PCa treatment
- If already started ADT, have received no more than eight weeks ADT at randomisation
- Planned for radiotherapy
- Assessed by clinical team to be safe to exercise and safe to enter the trial with no absolute contraindications to exercise as defined by clinical guidance
- Able to use technological aspects of the intervention including access to MyMarsden and a device for video conferencing
- Fluent in English and able to understand instructions
- WHO performance status 0-2
- Able to give written informed consent
Age in the registry: 18 years to - · Sex: Male · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| The Royal Marsden Hospital Coordinator of this site? Confirm its status | London | United Kingdom | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.